Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Ustekinumab Induction and Maintenance in Moderately to Severely Active Ulcerative Colitis
jRCT2080223068Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in autoimmune colitis (8 arms), sponsored by Janssen Pharmaceutical. Started Jan 2016; status: completed.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080223068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223068.